Novartis: Hemoglobinuria, Paroxysmal trials

The registry lists 16 Hemoglobinuria, Paroxysmal studies with Novartis as lead sponsor. 6 are open to participants now and 6 have results posted.

Phase 2 3Phase 3 5No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 GlomerulopathyRecruitingNCT07416162
• REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaRecruitingNCT07229235
• Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsRecruitingNCT06934967Phase 3
• A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in ChinaRecruitingNCT06931691
• Home Reported Outcomes in PNHRecruitingNCT06411626
• Managed Access Programs for LNP023, IptacopanAvailableNCT05222412
• Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.CompletedNCT05630001Phase 3Results posted
• Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyCompletedNCT04820530Phase 3Results posted
• Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentCompletedNCT04558918Phase 3Results posted
• Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT03896152Phase 2Results posted
• Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT03439839Phase 2Results posted
• Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT02534909Phase 2Results posted
• NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical PracticeTerminatedNCT07036718
• Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH RegistryActive, not recruitingNCT06903234
• Specified Drug-use Surveillance of Fabhalta CapsulesActive, not recruitingNCT06606314
• Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT04747613Phase 3